查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867515

腎上腺腦白質營養不良症治療：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Adrenoleukodystrophy Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 82 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球腎上腺腦白質營養不良症治療市場預計在 2024 年達到 2.53 億美元，預計到 2031 年將達到 5.91 億美元，2025 年至 2031 年的複合年成長率為 10.9%。

腎上腺腦白質營養不良症 (ALD) 的治療方法旨在預防、延緩或逆轉由 ABCD1 基因突變導致中樞神經系統和腎上腺中極長鏈脂肪酸 (VLCFA) 積累引起的神經退化和內分泌症狀。治療治療方法包括旨在調節脂肪酸代謝和緩解症狀的代謝干預；造血幹細胞移植 (HSCT) 相關療法，如果早期應用，可以阻止腦部疾病的進展；以及近年來出現的單劑量基因替代療法，該療法可糾正自體細胞中的潛在基因缺陷。臨床策略因表現型而異，包括兒童腦型 ALD (CALD)、腎上腺髓鞘形成性神經病變 (AMN) 和腎上腺功能不全，每種表現型的作用機制、給藥途徑和調控路徑都各不相同。基因療法為早期活動性腎上腺腦白質營養不良症（ALD）且缺乏匹配供體的男性患者提供了一種創新的單劑量治療選擇，但同時也需要長期的安全監測以及複雜的商業化和報銷問題。總而言之，從傳統的支持療法到先進的細胞和基因療法，腎上腺腦白質營養不良症的治療正在重塑這一罕見疾病領域的臨床實踐、支付方評估以及研發重點。

在精準醫療的成熟和監管機構對罕見疾病創新優先發展的推動下，腎上腺腦白質營養不良症（ALD）治療領域正處於一個轉折點。單劑量基因替代療法的監管加速核准和有條件核准，為缺乏匹配供體的早期活動性腎上腺腦白質營養不良症患者開闢了一條商業性可行性的治療途徑，從而改變了臨床診療流程，並激勵支付方和醫療服務提供方協商長期、以療效為導向的契約。公共衛生措施以及新生兒和標靶篩檢計畫的擴展，提高了早期檢出率，並擴大了可進行治療性介入和高價值干預的患者群體。建構整合研發、生產和專業治療中心的協作交付模式的公司，能夠獲得差異化的市場進入和持續的臨床合作。

創新風險和商業化複雜性是主要的阻礙因素。儘管基因療法已展現出令人信服的療效，但長期安全性問題（尤其是與載體整合相關的骨髓惡性腫瘤）需要長期監測，這增加了監管標籤和醫保覆蓋範圍的複雜性，並影響了其推廣應用的速度。針對罕見疾病、高成本療法的差異化報銷給跨境產品推廣帶來了挑戰。自體細胞產品的生產和物流需要大量的資金和營運能力。患者群體本身規模較小且臨床表現多樣，限制了快速擴大規模和投資回報。公司申報文件和監管溝通凸顯了申辦者需要同時應對臨床、監管和衛生經濟方面的壓力。

下游需求正朝著「篩檢-治療-管理」一體化生態系轉變。新生兒篩檢篩檢率和特定疾病的篩檢率不斷提高，推動了對早期根治性治療（造血幹細胞移植或基因治療）的需求；同時，患者家屬和臨床醫生也需要可靠的長期安全性、生活品質和功能性結局數據，從而推動了對追蹤服務和支持性護理的需求。支付者越來越接受與長期療效掛鉤的創新報銷機制，迫使申辦方制定上市後證據產生策略和可擴展的追蹤基礎設施。因此，採購模式將從單一產品採購演變為結合診斷、治療和長期療效管理的捆綁式服務。

本報告旨在按地區/國家、類型和應用對全球腎上腺腦白質營養不良治療市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以收益為準，以2024年為基準年，對腎上腺腦白質營養不良症治療藥物市場規模、估計值和預測進行了闡述，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定腎上腺腦白質營養不良症治療藥物的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Bluebird Bio
  • NeuroVia
  • Orpheris
  • Minoryx
  • MedDay Pharmaceuticals
  • Rocket Pharmaceuticals
  • Lysogene
  • Sangamo Therapeutics

按類型分類的細分市場

  • 荷爾蒙補充療法
  • 移植
  • 其他

應用領域

  • 兒童腦血管酒精性肝病
  • 腎上腺髓鞘形成性神經病變（AMN）
  • 僅愛迪生氏症
  • 其他

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Adrenoleukodystrophy Drugs was estimated to be worth US$ 253 million in 2024 and is forecast to a readjusted size of US$ 591 million by 2031 with a CAGR of 10.9% during the forecast period 2025-2031.

Adrenoleukodystrophy (ALD) drugs are therapeutic solutions designed to prevent, slow, or reverse the neurodegenerative and endocrine manifestations caused by mutations in the ABCD1 gene, which lead to accumulation of very-long-chain fatty acids (VLCFAs) in the central nervous system and adrenal glands. The therapeutic landscape includes metabolic interventions (aimed at modulating fatty-acid metabolism and symptomatic support), hematopoietic stem cell transplant (HSCT)-related approaches that can arrest cerebral disease progression when performed early, and the more recent single-administration gene-replacement therapies that correct the underlying genetic defect in autologous cells. Clinical strategies differ markedly by phenotype - childhood cerebral ALD (CALD), adrenomyeloneuropathy (AMN), or adrenal insufficiency - and thus vary in mechanism of action, delivery modality, and regulatory pathway. Gene therapy introduces a potentially transformative one-time option for boys with early, active CALD who lack matched donors, while also imposing long-term safety monitoring and complex commercialization and reimbursement considerations. Overall, ALD drugs now span from conventional supportive regimens to advanced cell and gene therapeutics, reshaping clinical practice, payer evaluation, and R&D priorities in this ultra-rare disease area.

The ALD therapeutic space is experiencing an inflection point driven by the maturation of precision medicine and regulatory prioritization of rare-disease innovation. Regulatory acceleration and conditional approvals for one-time gene-replacement therapies have created a commercially viable pathway for treating boys with early, active CALD who lack matched donors-transforming clinical algorithms and motivating payers and providers to negotiate long-term outcome-based arrangements. Public health initiatives and expanded newborn or targeted screening programs are improving early detection rates, which in turn expand the addressable population for curative and high-value interventions. Companies that integrate R&D, manufacturing and Centers of Excellence into a coordinated delivery model can secure differentiated market access and durable clinical partnerships.

Innovation risk and commercialization complexity are prominent restraints. While gene therapies demonstrate compelling efficacy, long-term safety concerns-particularly vector integration-related hematologic malignancies-require extended monitoring and complicate regulatory labeling and payer coverage, thereby affecting adoption speed. Cross-border launches face heterogeneous reimbursement frameworks for ultra-rare, high-cost therapies; manufacturing and logistics for autologous cell-based products demand significant capital and operational capabilities. The patient population is inherently small and clinically heterogeneous, constraining rapid scale-up and return on investment. Company filings and regulatory communiques highlight that sponsors must manage clinical, regulatory and health-economic pressures in parallel.

Downstream demand is shifting toward an integrated "screen-treat-manage" ecosystem. Rising newborn and targeted screening rates will increase demand for early definitive interventions (HSCT or gene therapy), while families and clinicians will require robust long-term safety, quality-of-life, and functional-outcome data-driving growth in follow-up services and supportive care. Payers are increasingly receptive to innovative reimbursement constructs tied to long-term outcomes, prompting sponsors to design post-marketing evidence-generation strategies and scalable follow-up infrastructures. Consequently, procurement will evolve from single-product purchases toward bundled offerings that combine diagnostics, therapeutic delivery, and longitudinal outcomes management.

This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Adrenoleukodystrophy Drugs by region & country, by Type, and by Application.

The Adrenoleukodystrophy Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Drugs.

Market Segmentation

By Company

  • Bluebird Bio
  • NeuroVia
  • Orpheris
  • Minoryx
  • MedDay Pharmaceuticals
  • Rocket Pharmaceuticals
  • Lysogene
  • Sangamo Therapeutics

Segment by Type

  • Hormone Replacement
  • Transplant
  • Others

Segment by Application

  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Adrenoleukodystrophy Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Adrenoleukodystrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Adrenoleukodystrophy Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Adrenoleukodystrophy Drugs Product Introduction
  • 1.2 Global Adrenoleukodystrophy Drugs Market Size Forecast (2020-2031)
  • 1.3 Adrenoleukodystrophy Drugs Market Trends & Drivers
    • 1.3.1 Adrenoleukodystrophy Drugs Industry Trends
    • 1.3.2 Adrenoleukodystrophy Drugs Market Drivers & Opportunity
    • 1.3.3 Adrenoleukodystrophy Drugs Market Challenges
    • 1.3.4 Adrenoleukodystrophy Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Adrenoleukodystrophy Drugs Players Revenue Ranking (2024)
  • 2.2 Global Adrenoleukodystrophy Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Adrenoleukodystrophy Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Adrenoleukodystrophy Drugs
  • 2.6 Adrenoleukodystrophy Drugs Market Competitive Analysis
    • 2.6.1 Adrenoleukodystrophy Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Adrenoleukodystrophy Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Hormone Replacement
    • 3.1.2 Transplant
    • 3.1.3 Others
  • 3.2 Global Adrenoleukodystrophy Drugs Sales Value by Type
    • 3.2.1 Global Adrenoleukodystrophy Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Adrenoleukodystrophy Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Adrenoleukodystrophy Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Childhood Cerebral ALD
    • 4.1.2 Adrenomyeloneuropathy (AMN)
    • 4.1.3 Addison-only
    • 4.1.4 Others
  • 4.2 Global Adrenoleukodystrophy Drugs Sales Value by Application
    • 4.2.1 Global Adrenoleukodystrophy Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Adrenoleukodystrophy Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global Adrenoleukodystrophy Drugs Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Adrenoleukodystrophy Drugs Sales Value by Region
    • 5.1.1 Global Adrenoleukodystrophy Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Adrenoleukodystrophy Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Adrenoleukodystrophy Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Adrenoleukodystrophy Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.2.2 North America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.3.2 Europe Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Adrenoleukodystrophy Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.5.2 South America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.3.2 United States Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.5.2 China Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Adrenoleukodystrophy Drugs Sales Value, 2020-2031
    • 6.9.2 India Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Adrenoleukodystrophy Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Bluebird Bio
    • 7.1.1 Bluebird Bio Profile
    • 7.1.2 Bluebird Bio Main Business
    • 7.1.3 Bluebird Bio Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.1.4 Bluebird Bio Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Bluebird Bio Recent Developments
  • 7.2 NeuroVia
    • 7.2.1 NeuroVia Profile
    • 7.2.2 NeuroVia Main Business
    • 7.2.3 NeuroVia Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.2.4 NeuroVia Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 NeuroVia Recent Developments
  • 7.3 Orpheris
    • 7.3.1 Orpheris Profile
    • 7.3.2 Orpheris Main Business
    • 7.3.3 Orpheris Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.3.4 Orpheris Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Orpheris Recent Developments
  • 7.4 Minoryx
    • 7.4.1 Minoryx Profile
    • 7.4.2 Minoryx Main Business
    • 7.4.3 Minoryx Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.4.4 Minoryx Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Minoryx Recent Developments
  • 7.5 MedDay Pharmaceuticals
    • 7.5.1 MedDay Pharmaceuticals Profile
    • 7.5.2 MedDay Pharmaceuticals Main Business
    • 7.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 MedDay Pharmaceuticals Recent Developments
  • 7.6 Rocket Pharmaceuticals
    • 7.6.1 Rocket Pharmaceuticals Profile
    • 7.6.2 Rocket Pharmaceuticals Main Business
    • 7.6.3 Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.6.4 Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Rocket Pharmaceuticals Recent Developments
  • 7.7 Lysogene
    • 7.7.1 Lysogene Profile
    • 7.7.2 Lysogene Main Business
    • 7.7.3 Lysogene Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.7.4 Lysogene Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Lysogene Recent Developments
  • 7.8 Sangamo Therapeutics
    • 7.8.1 Sangamo Therapeutics Profile
    • 7.8.2 Sangamo Therapeutics Main Business
    • 7.8.3 Sangamo Therapeutics Adrenoleukodystrophy Drugs Products, Services and Solutions
    • 7.8.4 Sangamo Therapeutics Adrenoleukodystrophy Drugs Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Sangamo Therapeutics Recent Developments

8 Industry Chain Analysis

  • 8.1 Adrenoleukodystrophy Drugs Industrial Chain
  • 8.2 Adrenoleukodystrophy Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Adrenoleukodystrophy Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Adrenoleukodystrophy Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Adrenoleukodystrophy Drugs Market Trends
  • Table 2. Adrenoleukodystrophy Drugs Market Drivers & Opportunity
  • Table 3. Adrenoleukodystrophy Drugs Market Challenges
  • Table 4. Adrenoleukodystrophy Drugs Market Restraints
  • Table 5. Global Adrenoleukodystrophy Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Adrenoleukodystrophy Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Adrenoleukodystrophy Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Adrenoleukodystrophy Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Adrenoleukodystrophy Drugs
  • Table 10. Global Adrenoleukodystrophy Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Adrenoleukodystrophy Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Adrenoleukodystrophy Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Adrenoleukodystrophy Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Adrenoleukodystrophy Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Adrenoleukodystrophy Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Adrenoleukodystrophy Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Adrenoleukodystrophy Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Adrenoleukodystrophy Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Adrenoleukodystrophy Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Adrenoleukodystrophy Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Adrenoleukodystrophy Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Bluebird Bio Basic Information List
  • Table 32. Bluebird Bio Description and Business Overview
  • Table 33. Bluebird Bio Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Bluebird Bio (2020-2025)
  • Table 35. Bluebird Bio Recent Developments
  • Table 36. NeuroVia Basic Information List
  • Table 37. NeuroVia Description and Business Overview
  • Table 38. NeuroVia Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of NeuroVia (2020-2025)
  • Table 40. NeuroVia Recent Developments
  • Table 41. Orpheris Basic Information List
  • Table 42. Orpheris Description and Business Overview
  • Table 43. Orpheris Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Orpheris (2020-2025)
  • Table 45. Orpheris Recent Developments
  • Table 46. Minoryx Basic Information List
  • Table 47. Minoryx Description and Business Overview
  • Table 48. Minoryx Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Minoryx (2020-2025)
  • Table 50. Minoryx Recent Developments
  • Table 51. MedDay Pharmaceuticals Basic Information List
  • Table 52. MedDay Pharmaceuticals Description and Business Overview
  • Table 53. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of MedDay Pharmaceuticals (2020-2025)
  • Table 55. MedDay Pharmaceuticals Recent Developments
  • Table 56. Rocket Pharmaceuticals Basic Information List
  • Table 57. Rocket Pharmaceuticals Description and Business Overview
  • Table 58. Rocket Pharmaceuticals Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Rocket Pharmaceuticals (2020-2025)
  • Table 60. Rocket Pharmaceuticals Recent Developments
  • Table 61. Lysogene Basic Information List
  • Table 62. Lysogene Description and Business Overview
  • Table 63. Lysogene Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Lysogene (2020-2025)
  • Table 65. Lysogene Recent Developments
  • Table 66. Sangamo Therapeutics Basic Information List
  • Table 67. Sangamo Therapeutics Description and Business Overview
  • Table 68. Sangamo Therapeutics Adrenoleukodystrophy Drugs Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Adrenoleukodystrophy Drugs Business of Sangamo Therapeutics (2020-2025)
  • Table 70. Sangamo Therapeutics Recent Developments
  • Table 71. Key Raw Materials Lists
  • Table 72. Raw Materials Key Suppliers Lists
  • Table 73. Adrenoleukodystrophy Drugs Downstream Customers
  • Table 74. Adrenoleukodystrophy Drugs Distributors List
  • Table 75. Research Programs/Design for This Report
  • Table 76. Key Data Information from Secondary Sources
  • Table 77. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Adrenoleukodystrophy Drugs Product Picture
  • Figure 2. Global Adrenoleukodystrophy Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Adrenoleukodystrophy Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Adrenoleukodystrophy Drugs Report Years Considered
  • Figure 5. Global Adrenoleukodystrophy Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Adrenoleukodystrophy Drugs Revenue in 2024
  • Figure 7. Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Hormone Replacement Picture
  • Figure 9. Transplant Picture
  • Figure 10. Others Picture
  • Figure 11. Global Adrenoleukodystrophy Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Adrenoleukodystrophy Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Childhood Cerebral ALD
  • Figure 14. Product Picture of Adrenomyeloneuropathy (AMN)
  • Figure 15. Product Picture of Addison-only
  • Figure 16. Product Picture of Others
  • Figure 17. Global Adrenoleukodystrophy Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Adrenoleukodystrophy Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Adrenoleukodystrophy Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Adrenoleukodystrophy Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Adrenoleukodystrophy Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Adrenoleukodystrophy Drugs Sales Value (%), (2020-2031)
  • Figure 30. United States Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Adrenoleukodystrophy Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Adrenoleukodystrophy Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Adrenoleukodystrophy Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Adrenoleukodystrophy Drugs Industrial Chain
  • Figure 52. Adrenoleukodystrophy Drugs Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed